Adcetris Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) that targets CD30, a protein expressed on the surface of certain cancer cells, including those associated with Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It combines a monoclonal antibody with the cytotoxic agent monomethyl auristatin E (MMAE) to deliver targeted chemotherapy directly to cancer cells, enhancing treatment effectiveness while minimizing off-target side effects.

The main forms of Adcetris include powder and liquid. Adcetris is provided as a sterile, white to off-white lyophilized powder in single-dose vials, which healthcare professionals reconstitute with a specified volume of sterile water prior to intravenous infusion. The various indications include Hodgkin lymphoma, systemic anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, and others, and it is used across settings such as hospitals, drug stores, and other healthcare facilities.

Tariffs have impacted the adcetris market by increasing costs associated with imported biologic raw materials, specialized manufacturing inputs, and cold-chain logistics services. These added costs have influenced pricing strategies and reimbursement discussions, particularly in emerging oncology markets dependent on imports. Hospital and specialty pharmacy segments in regions such as asia pacific and latin america have experienced greater sensitivity due to higher import reliance. At the same time, tariffs have encouraged manufacturers to invest in localized biologics manufacturing and regional supply hubs. This shift supports long-term supply stability and reduces future exposure to cross-border trade disruptions.

The adcetris market research report is one of a series of new reports from The Business Research Company that provides adcetris market statistics, including adcetris industry global market size, regional shares, competitors with a adcetris market share, detailed adcetris market segments, market trends and opportunities, and any further data you may need to thrive in the adcetris industry. This adcetris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adcetris market size has grown strongly in recent years. It will grow from $1.4 million in 2025 to $1.52 million in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to advances in monoclonal antibody research, rising incidence of hodgkin lymphoma, unmet needs in relapsed cancers, clinical success of targeted therapies, regulatory approvals for adc drugs.

The adcetris market size is expected to see strong growth in the next few years. It will grow to $2.12 million in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to expansion into additional indications, increasing oncology biologics investment, growth in personalized medicine adoption, rising healthcare expenditure on cancer, improved adc manufacturing scalability. Major trends in the forecast period include expanded use of antibody drug conjugates in oncology, growing preference for targeted cancer therapies, rising combination therapy adoption, increased focus on rare lymphoma treatments, improved clinical outcomes in cd30-positive cancers.

The increasing prevalence of cancer is expected to drive the growth of the Adcetris market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The rising incidence of cancer is attributed to factors such as unhealthy lifestyle choices, including poor diet and physical inactivity, greater exposure to environmental pollutants, and improvements in diagnostic techniques that enable earlier and more frequent detection. Adcetris provides notable benefits for cancer patients by selectively targeting CD30-positive cancer cells and delivering a potent cytotoxic agent directly to the tumor, which enhances treatment effectiveness while reducing systemic side effects. This targeted approach offers an important therapeutic option for patients with certain forms of Hodgkin lymphoma and other malignancies that express CD30. For example, in January 2023, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, approximately 1,958,310 new cancer cases were reported in the United States in 2023, along with 609,820 cancer-related deaths. Therefore, the growing burden of cancer is contributing to the expansion of the Adcetris market.

A key trend shaping the Adcetris market is the emphasis on developing improved antibody-drug conjugates (ADCs) and enhanced drug-delivery approaches, including combination therapies, to increase therapeutic efficacy, limit adverse effects, and more precisely target cancer cells. Combination therapies involve the use of two or more agents with different mechanisms of action, often working synergistically to improve treatment outcomes, reduce drug resistance, and potentially lower toxicity compared with single-agent therapy. For instance, in October 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, received approval from the European Commission for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of adults with previously untreated CD30-positive Stage III Hodgkin lymphoma. This antibody-drug conjugate targets CD30, a defining marker of Hodgkin lymphoma, and clinical trial results showed that the ADCETRIS-plus-AVD regimen significantly improved both modified progression-free survival and overall survival compared with standard therapies.

In January 2024, Pfizer Inc., a US-based pharmaceutical company, completed the acquisition of Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio by incorporating Seagen's innovative antibody-drug conjugates, including Adcetris, thereby expanding its targeted cancer therapy offerings, supporting growth in oncology, and accelerating the delivery of advanced cancer treatments to patients worldwide. Seagen Inc. is a US-based biotechnology company that develops and commercializes Adcetris.

Major companies operating in the adcetris market are Takeda Pharmaceutical Company Limited, Seagen Inc.

North America was the largest region in the adcetris market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adcetris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the adcetris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The adcetris market consists of sales of brentuximab vedotin-based therapies such as antibody-drug conjugates (ADCs), bispecific antibodies, and immune checkpoint inhibitors for the treatment of lymphoma and related cancers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adcetris Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses adcetris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adcetris ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The adcetris market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Powder; Liquid
• 2) By Indication: Hodgkin Lymphoma; Systemic Anaplastic Large Cell Lymphoma; Cutaneous T-Cell Lymphoma; Other Indication
• 3) By Application: Hospital; Drugs Store; Other Applications
• Companies Mentioned: Takeda Pharmaceutical Company Limited; Seagen Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.